tyramine
Small moleculeexperimental
Tyramine, also known under several other names, is a naturally occurring trace amine derived from the amino acid tyrosine. Tyramine acts as a catecholamine releasing agent. Notably, it is unable to cross the blood-brain barrier, resulting in only non-psychoactive peripheral sympathomimetic effects following ingestion. A hypertensive crisis can result, however, from ingestion of tyramine-rich foods in conjunction with the use of monoamine oxidase inhibitors (MAOIs). — Wikipedia
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 1996 (NCT00748059)
Timeline
Indications
Mechanism of action
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTyramine ↗
Also known as
- 2-(p-hydroxyphenyl)ethylamine
- p-hydroxyphenethylamine
- tyramine
- tyramine
- tyramine
- tyramine
- tyramine
- tyramine hcl
- tyramine hydrochloride
- tyrosamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03979820 | Phase 1 | Jul 8, 2019 | Boehringer Ingelheim |
| NCT03694119 | Phase 1 | Jul 24, 2018 | Celgene |
| NCT01539473 | Phase 1 | Feb 1, 2012 | Trius Therapeutics |
| NCT00203125 | Phase 3 | Oct 1, 2000 | Teva |
| NCT00748059 | Phase 1 | Dec 1, 1996 | Vanderbilt University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2019 |
| Celgene | For profit | 1 | 1 | 1 | 2018 |
| Teva | For profit | 1 | 1 | 1 | 2000 |
| Trius Therapeutics | For profit | 1 | 1 | 1 | 2012 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 1996 |
5 organizations
Page 1 / 1